Combining BRAFV600Einhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma

Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations

(2015) Monika Cierlitza et al.   EXPERIMENTAL DERMATOLOGY

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

Metformin—mode of action and clinical implications for diabetes and cancer

(2014) Ida Pernicova et al.   Nature Reviews Endocrinology

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

(2013) Rizwan Haq et al.   CANCER CELL

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma

(2013) P. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE